By Sam Boughedda
Large pharmaceutical companies are reportedly eyeing a potential takeover deal for Global Blood Therapeutics (NASDAQ: GBT ), according to a Bloomberg report Thursday.
Citing people familiar with the matter, the report states biopharmaceutical firm Global Blood Therapeutics is working with advisors to study potential interest, although there is no certainty a takeover will occur.
Global Blood Therapeutics shares jumped 36% following the news, their highest point since March 2021.
A Goldman Sachs analyst reacted to the report, maintaining a Buy rating and $66 price target.
"GBT is the rare commercial stage smid-cap biotech in the attractive sickle cell disease market with next generation pipeline assets advancing in the clinic. After market close on Wednesday (08/03), Bloomberg (LINK) reported that GBT is drawing takeover interest from large pharmaceutical companies, while also noting that there are multiple potential bidders, and that a deal is not certain," said the analyst.
"While we take no view on the likelihood of a potential transaction, we note that Oxbryta NRx growth has materially improved in 2022 after flat to slightly down trends during the COVID-19 pandemic, and a larger/stronger rare disease or hematology sales force could give it a better chance for even greater uptake and accessing new prescribers (thus expanding NRx). After a lull in biotech M&A, an acquisition of GBT would be consistent with the recent pick up in later-stage biotech deal announcements ( PFE /BHVN; BMY / TPTX ), in our view," added the analyst.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.